A long-standing explanation for MKD is being rewritten
For decades, scientists believed that the destructive inflammation seen in mevalonate kinase deficiency, or MKD, was driven mainly by macrophages, a type of immune cell known for producing inflammatory signals. That assumption shaped treatment strategies, but it never fully explained why many patients continued to suffer severe flares even when therapies aimed at macrophage-linked pathways were used.
New work from the Garvan Institute of Medical Research now challenges that framework. In a study published in Immunity, researchers report that natural killer cells, or NK cells, appear to play a central role in the disease. Instead of functioning as efficient front-line defenders, these cells are impaired in patients with MKD, and that malfunction can amplify inflammatory responses when infections occur.
The finding matters because MKD is a lifelong autoinflammatory disorder that can cause recurring high fevers, skin rashes, abdominal inflammation and joint pain. In severe cases, those episodes can become life-threatening. The disease is considered rare, affecting hundreds of diagnosed patients worldwide, but researchers say additional cases may go unrecognized.
What the study says is going wrong
NK cells normally help control infections by attacking compromised cells and releasing toxic granules to destroy them. According to the Garvan team, that system breaks down in MKD. The study describes NK cells whose toxic granules remain trapped inside the cell instead of moving into position for an effective strike.
That defect leaves the cells unable to do their usual job properly. Rather than containing problems early, the immune system appears to overreact, creating the sort of excessive inflammatory response that defines the disorder. The work therefore shifts attention from a macrophage-centered model toward a broader view in which NK-cell dysfunction is a major part of the disease mechanism.
This is more than a technical adjustment in immunology. If the underlying culprit is different from what clinicians assumed for years, then drug development and treatment decisions may need to change with it. That is especially important in a rare disease where patients often cycle through limited therapeutic options and still endure recurrent inflammatory crises.
Why the treatment implications stand out
The authors say the findings point to interferon gamma and the signaling pathways around it as promising therapeutic targets. In practical terms, that raises the possibility of using JAK inhibitors, medicines already used in other inflammatory conditions, for MKD patients whose disease remains uncontrolled.
Professor Mike Rogers, the study’s senior author, said the results set the stage for future clinical studies evaluating JAK inhibitors or other approaches aimed at neutralizing interferon gamma in people with MKD. That would represent a targeted strategy that, based on the article, has not previously been tried in this disorder.
The significance is twofold. First, JAK inhibitors are not merely theoretical molecules; they are an existing drug class with known clinical use in inflammatory medicine. Second, the new mechanism offers a more specific rationale for why they might help. In rare diseases, that combination can accelerate the path from biological insight to real-world testing.
Still, this remains a research-stage advance. The source material supports a strong mechanistic case, but it does not claim that JAK inhibitors have already been proven effective in MKD patients. Clinical trials or carefully designed treatment studies would be needed before practice changes broadly.
Why rare-disease research often turns on mechanism
MKD illustrates a common problem in rare inflammatory disorders: symptoms can be dramatic, but the underlying biology is often murky for years. When the mechanistic model is incomplete, treatments may blunt part of the immune response without addressing the deeper trigger. That can leave patients stuck with partial relief, repeated flares and ongoing uncertainty.
By identifying a dysfunction in NK cells, the Garvan study offers a cleaner hypothesis for how infection-related episodes escalate. It also helps explain why targeting established inflammatory signals alone has not solved the problem for everyone. The disease may not just be a matter of too much inflammation from one cell type; it may also be a failure of immune control from another.
That distinction could influence future diagnostics as well as therapy. If NK-cell impairment becomes a recognized signature of MKD, researchers may gain new ways to profile severity, understand variation between patients and identify who is most likely to benefit from pathway-specific treatment.
What comes next
The immediate next step is validation in clinical settings. Researchers will need to determine whether the mechanism seen in the study consistently maps onto patient outcomes and whether drugs that interfere with the implicated signaling pathways can reduce flares safely and effectively.
Even before that happens, the study has already achieved something important: it has broken a 30-year scientific consensus and replaced it with a more testable, therapeutically relevant explanation. In rare diseases, that kind of shift can be the difference between managing symptoms indefinitely and finally designing interventions that fit the biology.
For patients with MKD and the clinicians who treat them, the result is not a finished cure. It is a sharper target. After years of pursuing the wrong immune culprit, researchers may now have a clearer idea of where the disorder starts to go off course, and which existing drug strategies might be worth trying next.
Key points
- The study links MKD inflammation to dysfunctional natural killer cells.
- Researchers say the findings challenge a decades-old focus on macrophages.
- JAK inhibitors and interferon gamma-targeted approaches are now emerging as potential treatment avenues.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
